Pakistan Journal of Neurological
Sciences (PJNS)
Volume 14

Issue 3

Article 5

9-2019

Neurotoxicity in a young patient with diffuse Large b-cell
lymphoma after first dose of Intrathecal triple therapy.
Ali Sajjad
Aga Khan University, Karachi

Sajid Hameed
Aga Khan University, Karachi

Sara Khan
Aga Khan University, Karachi

Follow this and additional works at: https://ecommons.aku.edu/pjns
Part of the Neurology Commons

Recommended Citation
Sajjad, Ali; Hameed, Sajid; and Khan, Sara (2019) "Neurotoxicity in a young patient with diffuse Large bcell lymphoma after first dose of Intrathecal triple therapy.," Pakistan Journal of Neurological Sciences
(PJNS): Vol. 14 : Iss. 3 , Article 5.
Available at: https://ecommons.aku.edu/pjns/vol14/iss3/5

C A S E

R E P O R T

NEUROTOXICITY IN A YOUNG PATIENT WITH DIFFUSE
LARGE B-CELL LYMPHOMA AFTER FIRST DOSE OF
INTRATHECAL TRIPLE THERAPY.
Dr. Ali Sajjad1, Dr. Sajid Hameed 1, Dr. Sara Khan2
1: Neurology Resident,Department of Neurology,Aga Khan University. 2: Assistant Professor,Department of Neurology, Aga Khan University.

Correspondence to: Dr. Sajid Hameed, Neurology Resident,Department of Neurology, Aga Khan University. E-mail: sajid.hameed@aku.edu
Date of submission: May 10, 2019 Date of revision: June 25, 2019 Date of acceptance: June29, 2019

ABSTRACT:
Background: Intrathecal triple chemotherapy (ITT) including cytarabine arabinoside, methotrexate and glucocorticoids
is a standard regimen for prophylaxis and treatment of hematological malignancies, owing to their high proclivity for
invasion of the neuraxis. Unfortunately, intrathecal chemotherapy is associated with various neurological adverse
effects including seizures, encephalopathy, myelopathy, arachnoiditis and cauda/conus syndrome. We present a case
of 33-year-old lady with primary bone diffuse large B-cell lymphoma. She had received 4 cycles of R-CHOP* and later
2 cycles of R-DHAP**. The first dose of ITT was administered along with the last cycle of R-DHAP. On the third day
post-ITT, she developed acute bilateral lower limb flaccid paralysis followed by one episode of generalized tonic clonic
seizure. Brain and spine imaging revealed diffuse meningeal enhancement with abnormal signal intensity
predominantly in central gray matter, extending from C7 to T6 spine. Patient was given methylprednisolone, parenteral
folic acid and vitamin B12 replacement, followed by five sessions of intravenous immunoglobulin with no clinical
benefit. No further intrathecal chemotherapy was given after the event. Attempts to predict risk factors and treat
intrathecal chemotherapy-induced severe neurological adverse effects are largely discouraging.
* Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
** Rituximab, dexamethasone, high-dose cytarabine and cisplatin
Keywords: Intrathecal triple therapy; Diffuse large B cell lymphoma; Aseptic meningitis; myelopathy; Conus medullaris
syndrome; Cauda equina syndrome

INTRODUCTION: Owing to the high proclivity for
invasion of the neuraxis by hematological
malignancies,[1] intrathecal chemotherapy along with
systemic chemotherapy and optional cranial irradiation
are standard components for the regime used for
prophylaxis and treatment.[2] The intrathecal
chemotherapeutics include traditional methotrexate
(MTX) or cytarabine arabinoside (Ara-C) alone or in
combination with intrathecal glucocorticoids and
contemporary monoclonal antibodies e.g. rituximab
and trastuzumab. Considering at least additive, if not
synergistic, effects of the MTX and Ara-C together with
glucocorticoids,[3-5] various study groups prefer use of
conventionally labelled intrathecal triple therapy (ITT) as
a
preferred
regime.[6] Regrettably,
intrathecal
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chemotherapy is associated with well documented
neurological adverse effects including headache, visual
loss, seizures, aseptic meningitis, pseudotumor
cerebri,
encephalopathy,
leukoencephalopathy,
transverse myelopathy, radiculopathy, arachnoiditis and
cauda/conus syndrome.[3,7-8] We present a case of a
young lady with primary bone diffuse large B-cell
lymphoma that developed aseptic meningitis, acute
myelopathy, and cauda/conus syndrome after the first
dose of ITT.
Case presentation:
A 33-year-old lady presented in our Emergency
Department (ED) with an acute onset bilateral lower
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limb numbness that progressed to bilateral lower limb
weakness within a few hours. It was associated with
band-like chest pain, urinary retention and mild
headache. Three days prior to presentation, she had
received her first prophylactic ITT (Ara-C 50 mg,
hydrocortisone 50 mg and MTX 12.5 mg) as a part of
diffuse B-cell lymphoma treatment. On arrival, she had
an episode of generalized tonic clonic seizure in the
hospital, which was aborted with IV diazepam. Five
months back, she was first diagnosed with primary
diffuse large B-cell lymphoma of bone. It involved pelvic
bones, sternum and vertebral column (cervical, dorsal
and lumbar vertebrae) without spinal cord or
leptomeningeal involvement. Prior to her ITT, she had
received four cycles of standard R-CHOP chemotherapy
(rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisolone) followed by two cycles of R-DHAP
chemotherapy (rituximab, dexamethasone, high-dose
cytarabine and cisplatin). Cerebrospinal fluid (CSF)
studies and CSF cytology were unremarkable prior to
ITT. On examination, the patient was awake and alert
with intact higher mental functions. Cranial nerve
examination was unremarkable. Fundus examination
revealed normal optic discs bilaterally. There were no
signs of meningeal irritation. Motor examination
revealed normal tone and power in bilateral upper limbs
with Medical Research Council (MRC) grade of 5/5,
while the tone was reduced in bilateral lower limbs and
power was of MRC grade 0/5. Knee and ankle reflexes
were absent with equivocal plantar responses. On
sensory examination, all sensation modalities were
absent up-to sensory level T4. Abdominal reflex was
absent.

Figure 1. MRI cervical and upper thoracic spine
showing isointense signals on T1 (left) and
hyperintense on T2 MRI (right)

Figure 2. Pre and post contrast T1 MRI cervical
and upper thoracic spine showing minimal post
contrast enhancement (red arrow)

Investigations
With an initial impression of disease progression, MRI
of the brain and the whole spine with contrast were
done. MRI brain revealed diffuse meningeal
enhancement while MRI whole spine revealed new
longitudinal abnormal signal intensities in the spinal
cord, predominantly central gray matter, extending from
C7 to T6 levels. These signals were isointense on T1
and hyperintense on T2 (Figure 1) with minimal post
contrast enhancement (Figure 2), along with
enhancement of the conus medullaris and cauda
equina nerve roots (Figure 3). The heterogeneous T1
and T2 signal intensities in cervical, thoracic and
lumbar vertebral bodies and left iliac bone with patchy
post
contrast
enhancement
suggesting
old
lymphomatous deposits were also seen, which showed
no interval progression of disease.
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Figure 3. MRI lumbosacral spine showing
enhancement of the conus medullaris and cauda
equina nerve roots.
Nerve conduction studies and electromyography
(NCS/EMG) revealed no definite evidence of large fiber
sensory motor polyneuropathy. There was a complete
absence of voluntary motor unit potential activation in
lower limbs pointing towards a central disorder of motor
unit control. Serum B12 and folate levels were within
normal range.
CSF examination revealed CSF glucose of 68 mg/dL,
protein 294 g/dL and TLC 285/mm3, with
polymorphonuclear predominance (95%). Gram and
fungal stain were negative. A CSF biofire film array
panel for meningitis (DNA/RNA PCR panel) was sent to
detect 14 most common pathogens (including
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Streptococcus pneumoniae, Haemophilus influenzae,
Neisseria meningitidis, Herpes simplex, Varicella zoster,
Cytomegalovirus and Cryptococcus neoformans/gatti)
was also negative. CSF and blood culture did not grow
any organism. CSF cytology was negative for
malignancy.

Numerous mechanisms for non-leukemic neurotoxicity
have been postulated, varying from direct
toxicity/irritation by chemotherapeutics to neuropraxia
secondary to osmolarity changes.[10] While cytarabine
arabinoside directly hampers DNA synthesis of tumor
cells by inhibiting DNA polymerase, methotrexate
targets the same indirectly by inhibiting folic acid
enzymatic pathways.[7] The exact mechanism of
cytarabine neurotoxicity is unknown, Both cytarabine
and its metabolites can cause neurotoxicity through a
DNA synthesis-independent process since adult
neurons
are
postmitotic.[11]
Immune-mediated
mechanism by cytarabine might be also involved.[12]
Intrathecal methotrexate depletes local active
tetrahydrofolate synthesis, leading to methylcobalamin
and ultimately S-Adenosyl Methionine deficiency, an
indispensable requirement of myelin production.[13] It
results in central nervous system demyelination, which
is morphologically similar to that of subacute combined
degeneration of the spinal cord seen in vitamin B12
deficiency.[14] Finally, such rare but devastating adverse
effects in the presence of wide variety of dosages,
preservative compositions, dilutions, timings and
preparation protocols point toward potential of
idiosyncratic reactions and individual susceptibility
threshold to toxic effects of intrathecal chemotherapy.
[7]
Classically, intrathecal chemotherapy-induced
myelopathy has been reported to affect predominantly
posterior-lateral column.[10,14,15] However, exceptions
are not unusual and MRI findings often lag behind
clinical findings. Imaging may be initially normal or
show non-specific findings including cord edema,
central gray matter T2 hyperintensity and subtle
peripheral or diffuse meningeal enhancement along the
cord, conus medullaris and/or cauda equina.[8,14,16] In
our case, MRI spine shows predominantly central gray
matter involvement similar to only reported case by
Counsel P. et al. [16] Enhancement of conus medullaris
and cauda equina is also an established finding.[8,14]
Due to myelopathy at cervical and thoracic area,
cauda/conus syndrome symptoms were likely masked
and could not be assessed clinically in our patient until
appreciated on MRI of the spine. Although CSF studies
were suggestive of acute bacterial meningitis in our
patient, the close temporal association of intrathecal
chemotherapy and symptoms, unremarkable workup
for infection and lack of clinical deterioration after
stopping antibiotics in first few days favor aseptic
meningitis. CSF studies in chemotherapy-induced
chemical meningitis may vary from predominant
mononuclear cells to polymorphonuclear reaction with
increased proteins. [17] Cachia D. and colleagues
reported a case series of 7 patients with intrathecal

Treatment and Follow Up
She was initially started on meningitic doses of
vancomycin, ceftriaxone and acyclovir, which were later
stopped after negative cultures. IV methylprednisolone
was also administered for three days (1000 mg/day) as
an empirical treatment for myelopathy. For suspicion of
methotrexate induced myelitis, leucovorin 15 mg IV
every 8 hours and cyanocobalamin 1000 mcg IV once
daily were also administered. During the course of
treatment, she remained afebrile and alert. Due to lack
of response to high-dose steroids, possibility of
paraneoplastic myelopathy was considered but serum
paraneoplastic antibodies were negative. She was also
administered
five
sessions
of
intravenous
immunoglobulins (IVIG). There was no neurologic
improvement and she was discharged with close
follow-up. No further intrathecal chemotherapy was
given after the event.Our initial differential diagnosis
included primary disease progression, paraneoplastic
neurotoxicity or chemotherapy induced neurotoxicity.
Primary disease progression was excluded as MRI
revealed no interval disease progression and two CSF
cytology studies were negative for malignancy. Workup
and treatment for paraneoplastic neurotoxicity were
also unrevealing. Hence, the diagnosis of ITT-induced
neurotoxicity i.e. aseptic meningitis, myelopathy and
cauda/conus syndrome was made as a diagnosis of
exclusion.
Discussion:
In the context of aggressive hematological
malignancies, with potential or established central
nervous system invasion, chemotherapy-induced
neurotoxicity poses potential diagnostic confusion with
disease advancement. The concern of disease
progression compels a physician to continue or
upgrade antineoplastic drugs. At the same time there is
risk of irreversible self-harm by the chemotherapy.
Predictable
risk
factors
for
intrathecal
chemotherapy-induced neurotoxicity still remain to be
evaluated. Few documented risk factors include
intrathecal MTX dose of 50 mg or higher, repeat
intrathecal injection within a week, concurrent systemic
chemotherapy, cranial irradiation and active CNS
disease.[7,9]
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ruling out alternative differentials using direct/indirect
evidences of disease progression. Since the
sensitivity of serial CSF cytology approaches 70%,
90% and 95%, [18] two unremarkable CSF cytology
studies, done within a week of intrathecal
chemotherapy, make malignant infiltration less likely
in our case.

chemotherapy-induced myelopathy and cauda/conus
syndrome. None of the patients had low CSF glucose
on CSF analysis, and only one patient had CSF white
cell count >5 while protein was elevated in all
subjects. Five out of seven patients also had
EMG/NCS done and 3 of them had evidence of
concurrent
severe
polyneuropathy
or
polyradiculoneuropathy after intrathecal triple
therapy, with 2 of the patients also showing contrast
enhancement along conus medullaris and cauda
equina.[14] In our patient, EMG NCS done within 24
hours, was unrevealing and suggestive of central
cause with no evidence of neuropathy in the presence
of imaging evidence of enhancement along conus
medullaris and cauda equina which could not be
clinically assessed due to concurrent myelopathy.
Our patient did not respond to parenteral high dose
folic acid and B12 replacement. Although,
dextromethorphan,
high-dose
leucovorin,
cyanocobalamin and methionine replacement have
been tried with optimistic results in few studies.[13,14]
Since
further
intrathecal
chemotherapy
is
contraindicated in case of severe neurotoxicity,
despite a persistently low but definite index of
suspicion of disease progression, we did not give
further intrathecal chemotherapy after the event. This
is in contrast to Cachia. D. et al who continued IT
chemotherapy for at least one further cycle in all 7
patients with intrathecal myelopathy. 2 patients out of
7 improved temporarily after discontinuation of
chemotherapy and treatment with dextromethorphan.
However, they were also given other concurrent
treatments (e.g. steroids, IVIG) making it difficult to
attribute it to single treatment alone. The treatments
for these 7 patients ranged from the use of high dose
steroids to intravenous immunoglobulin to radiation
therapy with no difference in the outcome as in our
case.[14] Though intrathecal chemotherapy-induced
aseptic meningitis is usually reversible without any
definitive treatment,[17] myelopathy, conus medullaris
and cauda equina syndrome are notoriously
irreversible with promising response to folic acid
metabolite replacements in few cases only and no
response to steroids, plasmapharesis and IVIG in
various studies.[13,14]

Learning Points:
1. Triple intrathecal chemotherapy (ITT) is
associated with well-documented neurological
adverse effects including aseptic meningitis,
pseudotumor cerebri, transverse myelopathy,
arachnoiditis and cauda/conus syndrome.
2. Due to variable ITT protocol, predictability of risk
factor is difficult, few documented risk factors include
intrathecal MTX dose of 50 mg or higher, repeat
intrathecal injection within a week, concurrent
systemic chemotherapy, cranial irradiation and active
CNS disease.
3. Temporal association of new symptoms following
intrathecal chemotherapy creates a high-index of
suspicion of intrathecal triple therapy associated
neurotoxicity but other causes should be excluded
first.
4. Treatment options are limited, with variable
response
to
dextromethorphan,
leucovorin,
cyanocobalamin and methionine replacement in
literature.
5. Further
intrathecal
chemotherapy
is
contraindicated in case of severe neurotoxicity.
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